Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.
Department of Genetics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Pharmacogenet Genomics. 2023 Jul 1;33(5):91-100. doi: 10.1097/FPC.0000000000000491. Epub 2023 Apr 24.
Renal toxicity is more common with tenofovir disoproxil fumarate (TDF) than with tenofovir alafenamide fumarate (TAF). We investigated whether polymorphisms in genes relevant to tenofovir disposition affect renal toxicity among HIV-positive Southern Africans.
Genetic sub-study of adults randomized to initiate TAF or TDF together with dolutegravir and emtricitabine was conducted. Outcomes were changes from week 4 to 48 in the estimated glomerular filtration rate (eGFR) and from baseline to week 48 in urine retinol-binding protein and urine β2-microglobulin adjusted for urinary creatinine (uRBP/Cr and uB2M/Cr). Primary analyses prioritized 14 polymorphisms previously reported to be associated with tenofovir disposition or renal outcomes, and all polymorphisms in 14 selected genes. We also explored genome-wide associations.
336 participants were enrolled. Among 14 polymorphisms of primary interest, the lowest P values for change in eGFR, uRBP/Cr, and uB2M/Cr were ABCC4 rs899494 ( P = 0.022), ABCC10 rs2125739 ( P = 0.07), and ABCC4 rs1059751 ( P = 0.0088); and in genes of interest, the lowest P values were ABCC4 rs4148481 ( P = 0.0013), rs691857 ( P = 0.00039), and PKD2 rs72659631 ( P = 0.0011). However, none of these polymorphisms withstood correction for multiple testing. Genome-wide, the lowest P values were COL27A1 rs1687402 ( P = 3.4 × 10 -9 ), CDH4 rs66494466 ( P = 5.6 × 10 -8 ), and ITGA4 rs3770126 ( P = 6.1 × 10 -7 ).
Two ABCC4 polymorphisms, rs899494 and rs1059751, were nominally associated with change in eGFR and uB2M/Cr, respectively, albeit in the opposite direction of previous reports. COL27A1 polymorphism was genome-wide significantly associated with change in eGFR.
与富马酸替诺福韦二吡呋酯(TDF)相比,替诺福韦艾拉酚胺富马酸盐(TAF)更易引起肾毒性。我们研究了与替诺福韦处置相关的基因多态性是否会影响南非 HIV 阳性患者的肾毒性。
对随机接受 TAF 或 TDF 联合多替拉韦和恩曲他滨治疗的成年人进行遗传子研究。结局指标为肾小球滤过率(eGFR)从第 4 周到第 48 周的变化以及尿视黄醇结合蛋白(uRBP)/肌酐(Cr)和尿β2-微球蛋白(uB2M)/Cr 的变化,后者通过尿肌酐进行了校正(uRBP/Cr 和 uB2M/Cr)。主要分析优先考虑了先前报道与替诺福韦处置或肾结局相关的 14 个多态性,以及 14 个选定基因中的所有多态性。我们还探索了全基因组关联。
共纳入 336 名参与者。在 14 个主要关注的多态性中,eGFR、uRBP/Cr 和 uB2M/Cr 变化的最低 P 值为 ABCC4 rs899494(P=0.022)、ABCC10 rs2125739(P=0.07)和 ABCC4 rs1059751(P=0.0088);在感兴趣的基因中,最低的 P 值为 ABCC4 rs4148481(P=0.0013)、rs691857(P=0.00039)和 PKD2 rs72659631(P=0.0011)。然而,这些多态性没有一个能经受住多重检验的校正。全基因组范围内,最低的 P 值为 COL27A1 rs1687402(P=3.4×10-9)、CDH4 rs66494466(P=5.6×10-8)和 ITGA4 rs3770126(P=6.1×10-7)。
两个 ABCC4 多态性 rs899494 和 rs1059751 分别与 eGFR 和 uB2M/Cr 的变化呈名义相关,尽管与之前的报告方向相反。COL27A1 多态性与 eGFR 的变化呈全基因组显著相关。